Renal Cancer Detection With Liquid Biopsy (GaGnostic)

Zealand University Hospital

Status

Enrolling

Conditions

Oncocytoma

Renal Cancer

Treatments

Diagnostic Test: GaGnostic

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT05060783

SJ-894

Details and patient eligibility

About

Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer.
For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen)
Sign up information consent
Can perform protocol procedure

Exclusion criteria

Non-clear cell Renal cell carcinoma
RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney
Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.